Allens

Deutsche Bank Place Corner Hunter and Phillip Streets Sydney NSW 2000 Australia

T +61 2 9230 4000 F +61 2 9230 5333 www.allens.com.au GPO Box 50 Sydney NSW 2001 Australia

ABN 47 702 595 758



2 July 2024

Market Announcements Office ASX Limited 20 Bridge Street Sydney NSW 2000 Australia **By e-lodgement**

Dear Sir/Madam

Notice of ceasing to be a substantial holder in Telix Pharmaceuticals Limited (ASX:TLX)

As detailed in the registration statement relating to Telix Pharmaceuticals Limited's (*TLX*) proposed initial public offering in the United States of America (*US*) of American Depositary Shares, Jefferies LLC, Morgan Stanley & Co. LLC, Truist Securities, Inc., William Blair & Company, L.L.C. (together, the *Joint Lead Managers*) and certain director and management shareholders of TLX entered into lock-up agreements in relation to TLX securities. Under the *Corporations Act 2001* (Cth) (*Corporations Act*), entry into these lock-up agreements gave each Joint Lead Manager a 'Relevant Interest' (as defined in the Corporations Act) in the TLX securities that were the subject of the lock-up agreements. These interests were disclosed to the ASX in the form of substantial holder notices lodged on 21 May 2024.

Following TLX's announcement on 14 June 2024 that it had elected to withdraw from the US initial public offering process, the lock-up agreements have terminated, and the Joint Lead Managers have ceased to hold a Relevant Interest in the securities that were the subject of the lock-up agreements. Accordingly, a ceasing to be a substantial holder notice in relation to these interests accompanies this notice.

Yours faithfully

Adrian Amer Partner Allens Adrian.Amer@allens.com.au

T +61 2 9230 4000

Michael Burrell Senior Associate Allens Michael.Burrell@allens.com.au T +61 2 9230 4000

In alliance with Linklaters

Form 605 Corporations Act 2001

Section 671B

Notice of ceasing to be a substantial holder

To Company Name/Scheme	Telix Pharmaceuticals Limited (<i>TLX</i>)				
ACN/ARSN	ACN 616 620 369				
1. Details of substantial holder (1)					
Name	Truist Securitie	es, Inc. (<i>Truist</i>) and Truist Financial Corporation (<i>TFC</i>) (collectively the <i>Substantial Holders</i>)			
ACN/ARSN (if applicable)	N/A				
The holder ceased to be a substantial ho The previous notice was given to the cor		30/06/2024 21/05/2024			
The previous notice was dated		21/05/2024			

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Class (6) and number of securities affected	Person's votes affected
30/06/2024	Substantial Holders	Cessation of a relevant interest under ss608(1)(c) and 608(3) of the <i>Corporations Act 2001</i> (Cth) (Corporations Act) as a result of termination of the lock up agreements (see Annexure A to the Form 603 lodged by the Substantial Holders, dated 21 May 2024) in relation to TLX's public offering in the United States of America of American Depositary Shares.	52,152,624 Ordinary Shares	52,152,624

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN applicable)	Nature of association
N/A	

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Truist	3333 Peachtree Road NE, 11th Floor, Atlanta, Georgia 30308, USA
TFC	214 North Tryon Street, Charlotte, North Carolina, 28202, USA

Signature

print name	Lorenzo Paoletti	capacity	Managing Director, Head of Biotech Investment Banking
sign here	Jacob Parletti	date	1/07/2024